Vimarsana
Biggest News Aggregation in the World

Page 5 - Nasdaq Cccc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Cccc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Cccc Today - Breaking & Trending Today

C4 Therapeutics, Inc. (NASDAQ:CCCC) Forecasted to Post FY2023 Earnings of ($2.84) Per Share - Vimarsana News

C4 Therapeutics, Inc. (NASDAQ:CCCC) Forecasted to Post FY2023 Earnings of ($2.84) Per Share

C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) – Stock analysts at HC Wainwright cut their FY2023 EPS estimates for C4 Therapeutics in a report released on Monday, May 8th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($2.84) for the year, down from their previous estimate of […]

HC Wainwright Trims C4 Therapeutics (NASDAQ:CCCC) Target Price to $25.00 - Vimarsana News

HC Wainwright Trims C4 Therapeutics (NASDAQ:CCCC) Target Price to $25.00

C4 Therapeutics (NASDAQ:CCCC – Get Rating) had its price objective decreased by HC Wainwright from $35.00 to $25.00 in a research report sent to investors on Monday, The Fly reports. HC Wainwright also issued estimates for C4 Therapeutics’ FY2023 earnings at ($2.84) EPS, FY2024 earnings at ($3.06) EPS, FY2025 earnings at ($3.42) EPS, FY2026 earnings […]

Contrasting C4 Therapeutics (NASDAQ:CCCC) & Voyager Therapeutics (NASDAQ:VYGR) - Vimarsana News

Contrasting C4 Therapeutics (NASDAQ:CCCC) & Voyager Therapeutics (NASDAQ:VYGR)

C4 Therapeutics (NASDAQ:CCCC – Get Rating) and Voyager Therapeutics (NASDAQ:VYGR – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations. Institutional and Insider Ownership 80.3% of C4 Therapeutics shares […]

C4 Therapeutics (NASDAQ:CCCC) PT Lowered to $25.00 at HC Wainwright - Vimarsana News

C4 Therapeutics (NASDAQ:CCCC) PT Lowered to $25.00 at HC Wainwright

C4 Therapeutics (NASDAQ:CCCC – Get Rating) had its price target lowered by HC Wainwright from $35.00 to $25.00 in a research note published on Monday morning, The Fly reports. HC Wainwright also issued estimates for C4 Therapeutics’ FY2023 earnings at ($2.84) EPS, FY2024 earnings at ($3.06) EPS, FY2025 earnings at ($3.42) EPS, FY2026 earnings at […]

Source: wkrb13.com
ageas SA/NV (OTCMKTS:AGESY) Upgraded at ING Group - Vimarsana News

ageas SA/NV (OTCMKTS:AGESY) Upgraded at ING Group

C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) has been assigned a consensus rating of “Hold” from the seven research firms that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. […]